Verastem, Inc.
Novel cancer therapeutic molecules and drugs
- Sector
- Biotech
- Headquarters
- NEEDHAM, MA
- Founded
- 2010
- Latest Form D
- $100M, Mar 2020
- Total capital
- $163M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $163M
- 6 Form D · last Mar 2020
- 80 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 31 pending · first 2015
- Rank in peer group#179 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$100M
- Private capital raisedForm D · SEC · 5th filing$4.8M
- Private capital raisedForm D · SEC · 4th filing$3.9M
- Private capital raisedForm D · SEC · 3rd filing$2M
- Private capital raisedForm D · SEC · 2nd filing$20.1M
- Private capital raisedForm D · SEC · 1st filing$32M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#179 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- ALISON C. LAWTONDirectorNamed in SEC Form D filings
- AMY C. CAVERSExecutive OfficerNamed in SEC Form D filings
- Ansbert K. GadickeDirectorNamed in SEC Form D filings
- BRIAN STUGLIKExecutive Officer, DirectorNamed in SEC Form D filings
- BRUCE WENDELDirectorNamed in SEC Form D filings
- CATHY CAREWExecutive OfficerNamed in SEC Form D filings
Show all 26 people
- Christoph WestphalExecutive Officer, DirectorNamed in SEC Form D filings
- DAN K. PATERSONExecutive OfficerNamed in SEC Form D filings
- ERIC C. ROWINSKYDirectorNamed in SEC Form D filings
- GINA C. CONSYLMANDirectorNamed in SEC Form D filings
- Henri K. TermeerDirectorNamed in SEC Form D filings
- JOANNA K. HOROBINExecutive OfficerNamed in SEC Form D filings
- John K. ClarkeDirectorNamed in SEC Form D filings
- JOHN K. GREENExecutive OfficerNamed in SEC Form D filings
- JONATHAN K. PACHTERExecutive OfficerNamed in SEC Form D filings
- LOUISE K. PHANSTIELDirectorNamed in SEC Form D filings
- MICHAEL KAUFFMANDirectorNamed in SEC Form D filings
- MONICA K. SINGHExecutive OfficerNamed in SEC Form D filings
- Paul BrannellyExecutive OfficerNamed in SEC Form D filings
- Piyush K. GuptaDirectorNamed in SEC Form D filings
- Richard AldrichDirectorNamed in SEC Form D filings
- ROBERT FORRESTERExecutive OfficerNamed in SEC Form D filings
- ROB GAGNONExecutive OfficerNamed in SEC Form D filings
- STEPHEN K. KRAUSDirectorNamed in SEC Form D filings
- STEPHEN K. SHERWIN, M.D.DirectorNamed in SEC Form D filings
- TIMOTHY C. BARBERICHDirectorNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 40- PendingCombination Therapy For Treating Abnormal Cell GrowthUSPTOApplication 19561954
- GrantedSolid Forms Of A Dual Raf/mek InhibitorUSPTOUS 12,509,450
- PendingCombination Therapy For Treating Abnormal Cell GrowthUSPTOApplication 18871048
Show all 40 patent records
- Combination Therapy For Treating Abnormal Cell GrowthJul 16, 2026 · Application 19561954Pending
- Solid Forms Of A Dual Raf/mek InhibitorDec 30, 2025 · US 12,509,450Granted
- Combination Therapy For Treating Abnormal Cell GrowthDec 4, 2025 · Application 18871048Pending
- Combination Therapy For Treating Abnormal Cell GrowthMar 27, 2025 · Application 18730905Pending
- Combination Therapy For Treating Abnormal Cell GrowthJan 9, 2025 · Application 18702569Pending
- Methods Of Treating Abnormal Cell GrowthNov 21, 2024 · Application 18704267Pending
- Combination Therapy For Treating Abnormal Cell GrowthApr 11, 2024 · Application 18263820Pending
- Solid Forms Of A Dual Raf/mek InhibitorJan 16, 2024 · US 11,873,296Granted
- Therapeutic Compositions, Combinations, And Methods Of UseJan 4, 2024 · Application 18085792Pending
- Combination Therapy For Treating Abnormal Cell GrowthOct 19, 2023 · Application 18005012Pending
- Methods And Compositions For Treating Abnormal Cell GrowthOct 12, 2023 · Application 17989006Pending
- Methods Of Treating Abnormal Cell GrowthJun 29, 2023 · Application 17921509Pending
- Combination Therapy For Treating Abnormal Cell GrowthMar 30, 2023 · Application 17795402Pending
- Therapeutic Compositions, Combinations, And Methods Of UseJan 31, 2023 · US 11,564,927Granted
- Methods And Compositions For Treating Abnormal Cell GrowthMay 14, 2020 · Application 16519605Pending
- Therapeutic Compositions, Combinations, And Methods Of UseJan 14, 2020 · US 10,532,056Granted
- Methods And Compositions For Treating Abnormal Cell GrowthSep 10, 2019 · US 10,406,158Granted
- Methods And Compositions For Treating Abnormal Cell GrowthMay 8, 2018 · US 9,962,385Granted
- Synthesis And Use Of Kinase InhibitorsNov 29, 2016 · US 9,505,719Granted
- Pyrimidine Substituted Purine Compounds As Kinase (s) InhibitorsJul 21, 2016 · Application 14828886Pending
- Oral Formulations Of Kinase InhibitorsJun 28, 2016 · US 9,375,402Granted
- Pyrimidine Substituted Purine Compounds As Kinase (s) InhibitorsSep 22, 2015 · US 9,138,437Granted
- Sulfonyl Amide Derivatives For The Treatment Of Abnormal Cell GrowthMar 19, 2015 · Application 14552153Pending
- Methods Of Identifying Gene Isoforms For Anti-cancer TreatmentsMar 12, 2015 · Application 14384000Pending
- Biomarkers For Cancer Stem Cells And Related Methods Of UseJan 29, 2015 · Application 14384026Pending
- Therapeutic Compositions And Related Methods Of UseNov 13, 2014 · Application 14362879Pending
- Pyrimidine Substituted Purine DerivativesMar 6, 2014 · Application 14076810Pending
- Methods Of Treating Abnormal Cell GrowthApplication 63274745Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63272899Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63203555Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication PCTUS2021041439Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63185695Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63185704Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63185651Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63185672Pending
- Methods Of Treating Abnormal Cell GrowthApplication PCTUS2021029435Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63146357Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63146376Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63146369Pending
- Combination Therapy For Treating Abnormal Cell GrowthApplication 63146395Pending
Related companies, and why
- Skye BioscienceSimilar federal contract value in Biotech · null in contracts
- LIGHT SWITCH BIO, LLCSimilar federal contract value in Biotech · null in contracts
- Artiva BiotherapeuticsSimilar federal contract value in Biotech · null in contracts
- Solve TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Andira Medicine Inc.Similar federal contract value in Biotech · null in contracts
- OnKure TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .